Floatz logo

Ratg

Sickle Cell Disease

Medical College of WisconsinPhase 2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
65/ 100

Competitive context

135 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

Ratg is also rated in:

Acute Myelogenous LeukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Myelodysplastic SyndromeDormant
CCC
Indicative ·
48 / 100
View asset →
Chronic Myelogenous LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →